Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma
Files in This Item:
|EVALUATION OF ONCOGENIC CYSTEINYL LEUKOTRIENE RECEPTOR 2 AS A THERAPEUTIC TARGET FOR UVEAL MELANOMA.pdf||393.46 kB||Adobe PDF||Download Request a copy|
|Title:||Evaluation of oncogenic cysteinyl leukotriene receptor 2 as a therapeutic target for uveal melanoma||Authors:||Slater, Kayleigh
Hoo, Pei Sian
Buckley, A. M.
Piulats, J. M.
|Permanent link:||http://hdl.handle.net/10197/9533||Date:||Sep-2018||Abstract:||Uveal melanoma is a rare, but deadly, form of eye cancer that arises from melanocytes within the uveal tract. Although advances have emerged in treatment of the primary tumour, patients are still faced with vision loss, eye enucleation and lethal metastatic spread of the disease. Approximately 50% of uveal melanoma patients develop metastases, which occur most frequently in the liver. Metastatic patients encounter an extremely poor prognosis; as few as 8% survive beyond 2 years. Understanding of the genetic underpinnings of this fatal disease evolved in recent years with the identification of new oncogenic mutations that drive uveal melanoma pathogenesis. Despite this progress, the lack of successful therapies or a proven standard-of-care for uveal melanoma highlights the need for new targeted therapies. This review focuses on the recently identified CYSLTR2 oncogenic mutation in uveal melanoma. Here, we evaluate the current status of uveal melanoma and investigate how to better understand the role of this CYSLTR2 mutation in the disease and implications for patients harbouring this mutation.||Funding Details:||European Commission Horizon 2020
European Commission - Seventh Framework Programme (FP7)
Irish Research Council
|Type of material:||Journal Article||Publisher:||Springer||Journal:||Cancer Metastasis Reviews||Volume:||37||Issue:||2-3||Start page:||335||End page:||345||Copyright (published version):||2018 Springer||Keywords:||Cysteinyl leukotriene receptor 2; Cysteinyl leukotriene signalling; Patient-derived xenograft models; Uveal melanoma||DOI:||10.1007/s10555-018-9751-z||Language:||en||Status of Item:||Peer reviewed||metadata.dc.date.available:||2018-10-30T12:25:56Z|
|Appears in Collections:||Conway Institute Research Collection|
Biomolecular and Biomedical Science Research Collection
Show full item record
This item is available under the Attribution-NonCommercial-NoDerivs 3.0 Ireland. No item may be reproduced for commercial purposes. For other possible restrictions on use please refer to the publisher's URL where this is made available, or to notes contained in the item itself. Other terms may apply.